sibutramine has been researched along with Metabolic Diseases in 2 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, we demonstrated that sibutramine treatment had a favourable effect on body weight maintenance and obesity-related health risks." | 7.77 | Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. ( Hainer, V; Hainerová, IA; Sedláčková, D; Zamrazilová, H, 2011) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 7.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| " In addition, we demonstrated that sibutramine treatment had a favourable effect on body weight maintenance and obesity-related health risks." | 3.77 | Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. ( Hainer, V; Hainerová, IA; Sedláčková, D; Zamrazilová, H, 2011) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 3.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phillips, CL | 1 |
| Yee, BJ | 1 |
| Trenell, MI | 1 |
| Magnussen, JS | 1 |
| Wang, D | 1 |
| Banerjee, D | 1 |
| Berend, N | 1 |
| Grunstein, RR | 1 |
| Hainerová, IA | 1 |
| Zamrazilová, H | 1 |
| Sedláčková, D | 1 |
| Hainer, V | 1 |
2 other studies available for sibutramine and Metabolic Diseases
| Article | Year |
|---|---|
Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Appetite Depressants; Biomarkers; Cardiovascular Diseases; C | 2009 |
Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks.
Topics: Adult; Appetite Depressants; Body Composition; Body Weight; Cyclobutanes; Gonadotropins; Homozygote; | 2011 |